NCT02808026View on ClinicalTrials.gov

Study of CS-3150 in Patients With Severe Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

February 28, 2017

Study Completion Date

February 28, 2017

Conditions
Severe Hypertension
Interventions
DRUG

CS-3150

CS-3150 2.5 to 5mg, orally, once daily after breakfast

Trial Locations (1)

Unknown

Sapporo

Sponsors
All Listed Sponsors
lead

Daiichi Sankyo Co., Ltd.

INDUSTRY